September 5th 2024
During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lenalidomide Approved by the FDA for the Treatment of Mantle Cell Lymphoma
June 6th 2013Lenalidomide has been approved to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Read More
Study of Inotuzumab Ozogamicin Halted After Interim Analysis
May 22nd 2013A phase III study of inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.
Read More
Potential Therapeutic Target Identified in Acute Myeloid Leukemia
May 17th 2013Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.
Read More